Research progress of the combined application of immune checkpoint inhibitors in the treatment of hepatocellular carcinoma with portal vein tumor thrombus

VernacularTitle:联合应用免疫检查点抑制剂在肝细胞癌合并门静脉癌栓治疗中的研究进展
Author: Huimin MO ¹ ; Yusen CAI ; Zengrui ZHANG ; Wentian ZHU
Author Information

1. 广东医科大学第一临床学院，湛江　524000
Keywords: Carcinoma, hepatocellular; Portal vein cancer thrombus; Immune checkpoint inhibitors; Combination therapy
From: Journal of International Oncology 2024;51(8):520-525
CountryChina
Language:Chinese
Abstract: Portal vein tumor thrombus (PVTT) is one of the common complications of hepatocellular carcinoma (HCC) with a high mortality rate. Several studies have shown that active implementation of effective treatment can significantly improve the quality of life and prolong survival of HCC patients with PVTT. In recent years, with the continuous development of molecular biology and molecular immunology, the treatment of advanced liver cancer has shifted from single agent to combination therapy, among which, the combination of immune checkpoint inhibitors and other systemic or local therapies has attracted much attention. This treatment strategy has shown good efficacy in some large-scale clinical trials. With the deepening of relevant research, it is believed that this treatment scheme will bring more hope and opportunities to such patients.